Jakafi (Ruxolitinib Phosphate) Patent Expiration, LOE Window & CMS Spending
Jakafi (Ruxolitinib Phosphate) by Incyte: FDA Orange Book core substance LOE 2028-12-12 (last listed 2029-03-22), 0 AB generics, $2.24B 2024 CMS Part D & Medicaid spend, and 15 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Incyte |
| FDA Application & Pathway | N202192 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2028-12-12 |
| Last Listed Patent or Exclusivity Date | 2029-03-22 |
| Orange Book Patents (*PED Extensions) | 16 patents (8 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $2.24B |
| 2024 Medicare Part D Spend | $2.08B |
| 2024 Medicaid Spend | $161.4M |
| Reported Wholesale Price Change (CA SB 17) | 15 WAC filings (max 20.0% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.